Secondly, high heterogenicity in the tumor with SWI/SNF deficiency might also be responsible for the seemingly conflicting results in the studies about the response to ICI treatment in NSCLC patients and alterations in SWI/SNF. This evidence concerns the gene SMARCA1 and non-small cell lung carcinoma.